Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21478647 | 0.83 | HTR2A (0.47) | HTR2AHTR2CHTR2BALDH1A1RAB9A | |
| SCHEMBL12804213 | 0.80 | HTR2A (0.47) | HTR2AHTR2CHTR2BALDH1A1RAB9A | |
| SCHEMBL26606694 | 0.80 | ALDH1A1 (0.40) | HTR2AHTR2CHTR2BALDH1A1RAB9A | |
| SCHEMBL5395348 | 0.80 | HTR2A (0.42) | HTR2AHTR2CHTR2BALDH1A1RAB9A | |
| SCHEMBL29512955 | 0.80 | HTR2A (0.42) | HTR2AHTR2CHTR2BALDH1A1RAB9A | |
| SCHEMBL7939401 | 0.78 | HTR2A (0.42) | HTR2AHTR2CHTR2BALDH1A1RAB9A | |
| SCHEMBL374322 | 0.78 | GAA (0.43) | HTR2AHTR2CHTR2BALDH1A1RAB9A | |
| SCHEMBL23888219 | 0.77 | ALDH1A1 (0.42) | HTR2AHTR2CHTR2BALDH1A1RAB9A | |
| SCHEMBL15334770 | 0.77 | HTR2A (0.41) | HTR2AHTR2CHTR2BALDH1A1RAB9A | |
| SCHEMBL24572815 | 0.75 | IDO1 (0.44) | HTR2AHTR2CHTR2BALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755944-B1 | BIARYLDERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2017-06-14 | — | — | EP | claimed |
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | GENASE THERAPEUTICS B V (NL) | 2025-12-25 | — | — | US | disclosed |
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-02 | — | — | US | disclosed |
| EP-4469461-B1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B V (NL) | 2025-10-15 | — | — | EP | disclosed |
| CN-115557907-B | 2,4, 5-Trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-4469461-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | Genase Therapeutics B.V. (NL) | 2024-12-04 | — | — | EP | disclosed |
| CN-118946568-A | Tetrahydropyranopyrazole derivatives for the treatment of cancer and viral infections | 格纳赛治疗有限公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024184550-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-09-12 | — | — | WO | disclosed |
| CN-114174278-B | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-2755944-A2 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Fovea Pharmaceuticals (FR) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013037705-A9 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013037705-A9 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013037705-A2 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037705-A2 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-03-21 | — | — | WO | disclosed |
| EP-1549651-B1 | PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS | WARNER LAMBERT CO (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | HTR2A 4038/4885HTR2C 3651/4885HTR2B 4002/4885 |
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | CCNA1, KRAS, RSU1 | HTR2A 4497/4885HTR2C 3453/4885HTR2B 4520/4885 |
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | DHODH, DHPS, DPYD | HTR2A 3502/4885HTR2C 2201/4885HTR2B 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.